Molecular mechanisms of bipolar disorder

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 4, 2005, Pages 435-445

  Zarate Jr , Carlos A ^a   Singh, Jaskaran B ^a   Carlson, Paul J ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR ANTAGONIST; BUTYRIC ACID; CYCLOSERINE; DEXTRO SERINE; GLUCOCORTICOID RECEPTOR ANTAGONIST; GLUTAMIC ACID; GLYCINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INDIRUBIN; KETAMINE; LAMOTRIGINE; MALEIMIDE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; NEUROTRANSMITTER; PHOSPHODIESTERASE INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RILUZOLE; TALAMPANEL; TAMOXIFEN; UNINDEXED DRUG; VALPROIC ACID; ZINC;

AFFECT; AUTOPSY; BIPOLAR DISORDER; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DESIGN; DRUG MECHANISM; HUMAN; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROIMAGING; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 33645063445     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.11.005     Document Type: Review

References (25)

1. T.D. Gould et al. Emerging experimental therapeutics for bipolar disorder: Insights from the molecular and cellular actions of current mood stabilizers Mol. Psychiatry 9 2004 734-755
2. T.D. Gould et al. Glycogen synthase kinase-3: A target for novel bipolar disorder treatments J. Clin. Psychiatry 65 2004 10-21
3. T.D. Gould H.K. Manji Glycogen synthase kinase-3: A putative molecular target for lithium mimetic drugs Neuropsychopharmacology 30 2005 1223-1237
4. A. Martinez et al. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation Med. Res. Rev. 22 2002 373-384
5. D.C. Drummond et al. Clinical development of histone deacetylase inhibitors as anticancer agents Annu. Rev. Pharmacol. Toxicol. 45 2005 495-528
6. B. Langley et al. Remodeling chromatin and stress resistance in the central nervous system: Histone deacetylase inhibitors as novel and broadly effective neuroprotective agents Curr. Drug Targets CNS Neurol. Disord. 4 2005 41-50
7. I.C. Weaver et al. Epigenetic programming by maternal behavior Nat. Neurosci. 7 2004 847-854
8. G.S. Leverich et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network J. Clin. Psychiatry 64 2003 506-515
9. H.K. Manji R.H. Lenox Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness Biol. Psychiatry 46 1999 1328-1351
10. J.M. Bebchuk et al. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania Arch. Gen. Psychiatry 57 2000 95-97
11. H.K. Manji et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression Biol. Psychiatry 53 2003 707-742
12. C. D'Sa R.S. Duman Antidepressants and neuroplasticity Bipolar Disord. 4 2002 183-194
13. E.J. Nestler et al. Neurobiology of depression Neuron 34 2002 13-25
14. R.M. Sapolsky Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders Arch. Gen. Psychiatry 57 2000 925-935
15. J.A. Quiroz et al. Emerging experimental therapeutics for bipolar disorder: Clues from the molecular pathophysiology Mol. Psychiatry 9 2004 756-776
16. C.A. Zarate Jr. et al. An open-label trial of riluzole in patients with treatment-resistant major depression Am. J. Psychiatry 161 2004 171-174
17. C.A. Zarate Jr. et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression Biol. Psychiatry 57 2005 430-432
18. Zarate, C.A. et al. A double-blind placebo-controlled study of memantine in major depression. Am. J. Psychiatry (in press)
19. C.A. Zarate Jr. J.A. Quiroz Combination treatment in bipolar disorder: A review of controlled trials Bipolar Disord. 5 2003 217-225
20. C.A. Zarate et al. Modulators of the glutamatergic system: Implications for the development of improved therapeutics in mood disorders Psychopharmacol. Bull. 36 2002 35-83
21. G. Chen et. al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS J. Neurochem. 72 1999 879-882
22. G. Tsai J.T. Coyle N-Acetylaspartate in neuropsychiatric disorders Prog. Neurobiol. 46 1995 531-540
23. R.M. Sapolsky Is impaired neurogenesis relevant to the affective symptoms of depression? Biol. Psychiatry 56 2004 137-139
24. C.A. Zarate Jr. et al. Pramipexole for bipolar II depression: A placebo-controlled proof of concept study Biol. Psychiatry 56 2004 54-60
25. D.S. Charney H.K. Manji Life stress, genes, and depression: Multiple pathways lead to increased risk and new opportunities for intervention Sci. STKE 2004 2004 re5